October 2026
August 2026
- IndiviAmount not disclosed
Indivi develops smartphone-based assessments of motor and cognitive function to detect treatment effects earlier in neurology clinical trials.
- Vaderis TherapeuticsUSD 152 M
Vaderis Therapeutics develops targeted therapies for rare vascular diseases, including engasertib for hereditary haemorrhagic telangiectasia.
June 2026
- ClearideBio TherapeuticsAmount not disclosed
ClearideBio Therapeutics, founded in December 2025, develops antibody-drug conjugates against solid tumours.
May 2026
- NUCLIDIUMCHF 26 M
NUCLIDIUM develops copper-based radiotheranostics for cancer diagnosis and treatment.
- upVoltAmount not disclosed
upVolt extends the life of used lithium-ion batteries, turning them into second-life home batteries.
- Windward BioUSD 165 M
Windward Bio develops antibodies against immunological diseases, including WIN378, an anti-TSLP in phase 2/3 testing in asthma.
- BioCopyCHF 9 M
BioCopy develops TCR-mimetic bispecific antibodies against cancer, with an R&D site in Emmendingen, Germany.
April 2026
- Allegria TherapeuticsAmount not disclosed
Allegria Therapeutics develops mast cell-targeting therapies for allergic and inflammatory diseases.
- FERROSAUSD 3.5 M
FERROSA, founded in Basel in 2026 by Forty51 Ventures, is developing a bispecific antibody against inflammatory anaemia.
March 2026
- NanoZymeXCHF 150,000
A University of Basel spin-off, NanoZymeX is developing a lipid nanoparticle platform to improve enzyme replacement therapies.
- Umlaut.bioEUR 3 M
Umlaut.bio is developing small molecules that target transfer RNA modifications for cancer and inflammatory diseases.
- docdok.healthAmount not disclosed
docdok.health is developing ePACURA, an AI-assisted solution for structuring and using medical documentation.
February 2026
- AxmedUSD 6 M
Axmed runs a B2B platform for procuring and distributing essential medicines in low- and middle-income countries.
January 2026
- TECregenCHF 10 M
Founded in 2023, TECregen develops biologics aimed at regenerating the thymus to restore immune function.
December 2025
- FoRx TherapeuticsUSD 50 M
FoRx Therapeutics develops FORX-428, an oral PARG enzyme inhibitor for advanced solid tumours, now in Phase 1 trials.
- ALLEGRIA TherapeuticsUSD 5.1 M
Founded in 2023, ALLEGRIA Therapeutics develops therapies targeting mast cells to treat allergies and associated inflammatory diseases.
- Aukera TherapeuticsAmount not disclosed
A University of Basel spin-off, Aukera Therapeutics develops selective mTORC1 (RAPTOR) inhibitors, initially for tuberous sclerosis complex.
November 2025
- IndiviCHF 15 M
Indivi develops digital biomarkers that turn smartphones and everyday devices into measurement tools for neuroscience drug development.